• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Congress takes on FDA’s PET regulation

Article

The Food and Drug Administration's regulation of radioisotopes used in PET imaging has drawn the ire of Congress. Three members of the House of Representatives are circulating a "Dear Colleague" letter that urges support for legislation that would

The Food and Drug Administration's regulation of radioisotopes used in PET imaging has drawn the ire of Congress. Three members of the House of Representatives are circulating a "Dear Colleague" letter that urges support for legislation that would expressly remove the FDA's authority to regulate PET products.

The FDA has ruled that it has the authority to regulate PET radioisotopes produced in cyclotrons, and has proposed regulations requiring each isotope-producing site to receive new drug applications (NDAs) or abbreviated NDAs before their products can be used clinically. Opponents of the FDA's policy, however, believe that PET radioisotopes should be regulated under state practice of pharmacy rules. The FDA's policy prompted radiopharmacy firm Syncor International of Chatsworth, CA, to file suit against the FDA in 1995. A U.S. District Court decided in favor of the FDA late last year (SCAN 2/5/97).

The Dear Colleague letter was issued Feb. 27 by Rep. Richard Burr (R-NC), Rep. Gary Condit (D-CA), and Rep. Tom DeLay (R-TX). They are soliciting co-sponsors for the Pharmacy Compounding Act of 1997 (HR 1060), which would give the states regulatory authority over pharmacy compounding. It also includes a section that would withdraw the FDA's regulations regarding PET radioisotopes.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.